Torstila I, Kaukola S, Manninen V, Virtamo J, Mälkönen M
Acta Med Scand Suppl. 1982;668:123-9. doi: 10.1111/j.0954-6820.1982.tb08534.x.
The effects of gemfibrozil on plasma prekallikrein, kallikrein inhibitors, kininogen and plasma lipids were investigated in 31 male subjects having either type IIA or IIB dyslipidaemia. During gemfibrozil use, plasma prekallikrein and kininogen were increased significantly while kallikrein inhibitors increased only slightly. Total cholesterol and triglycerides decreased while HDL cholesterol was increased. Changes in prekallikrein and HDL cholesterol were correlated, whereas no other significant correlations between changes in lipid and kinin parameters were seen. The observed changes in prekallikrein and kininogen possibly indicate a shift in the thrombo-haemorrhagic balance in favour for increased fibrinolysis. If so, the effects of gemfibrozil in prevention and management of atherosclerosis would not be solely due to correlation of the dyslipidaemia but also to protection against the accelerated coagulation tendency seen in type II dyslipidaemia.
在31名患有IIA型或IIB型血脂异常的男性受试者中，研究了吉非贝齐对血浆前激肽释放酶、激肽释放酶抑制剂、激肽原和血浆脂质的影响。在使用吉非贝齐期间，血浆前激肽释放酶和激肽原显著增加，而激肽释放酶抑制剂仅略有增加。总胆固醇和甘油三酯降低，而高密度脂蛋白胆固醇增加。前激肽释放酶和高密度脂蛋白胆固醇的变化相关，而脂质和激肽参数变化之间未观察到其他显著相关性。前激肽释放酶和激肽原的观察变化可能表明血栓-出血平衡向有利于增强纤维蛋白溶解的方向转变。如果是这样，吉非贝齐在动脉粥样硬化预防和管理中的作用将不仅归因于血脂异常的相关性，还归因于对II型血脂异常中加速凝血倾向的保护。
